Pharmaceutical and biotech manufacturers benefit from the far-reaching expertise of the European market. Innovative and with the ability to save companies time and money, Route-to-market-Europe is a service package that provides smooth and direct access for companies wishing to enter new markets.
The new service package offered by pharmaceutical solution expert Movianto provides companies a smooth route-to-market when launching their products in a foreign territory. From consulting and regulatory affairs to the point of distribution and beyond, Movianto offers numerous vital services from under one roof, often reducing launch-to-market time by half.
This all-round offering is primarily of interest to pharmaceutical and biotech companies outside of Europe, often located in the US, that wish to launch their products in Europe themselves rather than outlicensing them to other pharmaceutical companies, thereby losing property of their products and certain rights. The service also benefits manufacturers of orphan drug medications against rare diseases as well as companies already located in Europe who have a niche portfolio of products.
The EU consists of 27 independent countries, which means there is a broad spectrum of laws and regulations that entail an almost insurmountable amount of research and administration work. The Movianto network is present in all major European locations and has acknowledged and experienced partners who specialise in pharmaceuticals and the complexities of the business.
Working in the field for many years has equipped the Movianto team with the skills and knowledge to efficiently and professionally handle the challenges that are involved with launching a new product in a new country or continent.
The Movianto network is in a position to develop a shortcut market entry strategy for a launch in Europe, allowing companies to concentrate on their core business without the need for diversification and being tied down to cumbersome research and tasks. Movianto's Route-to-Market-Europe service includes:
'We are aware of the hurdles that need to be overcome when successfully introducing a product to the European market,' explained Franz Bockhorni, sales director at Movianto. 'With the Route-to-Market-Europe offering, we have compiled our complete expertise into one package in order to ease the burden on niche companies wishing to introduce their products to the European market without using an out-licensing option.'
Regarding biotechnology, companies often require support along the complete supply chain when entering the market. To date, such organisations rely on consulting agencies that try and guide them through the labyrinth of European laws and regulations. Movianto's one-stop solution provides an all-encompassing professional service with one point of contact in the Movianto team.
'The product launch requires a specialised knowledge and skill set at every step,' says Bockhorni. 'Having to employ an expert in every one of these fields is not feasible in many companies. As specialists in the healthcare business, it is our job to anticipate the difficulties in the market for our clients and this is why we are offering this service, which is certainly proving to be popular.'
Movianto provides the pharmaceutical and biotechnology industry with innovative outsourcing supply-chain solutions across Europe. The one-stop-Route-to-market-Europe solution improves the product launch process in Europe by providing expert services regarding commercialisation from regulatory affairs, product release, sales and marketing to logistics and distribution.